BackBrooklyn ImmunoTherapeutics Overview

Brooklyn ImmunoTherapeutics Long Term Debt

Brooklyn ImmunoTherapeutics's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average / median

Loading

Brooklyn ImmunoTherapeutics Long Term Debt History

Loading

Brooklyn ImmunoTherapeutics vs. peers: Long Term Debt Comparison

Loading

Brooklyn ImmunoTherapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Brooklyn ImmunoTherapeutics (BTX) FAQ

Brooklyn ImmunoTherapeutics (BTX) currently reports a long-term debt of $0 as of December 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore Brooklyn ImmunoTherapeutics's long-term debt history and peer comparisons.

Brooklyn ImmunoTherapeutics's long-term debt changed from $0 to $0 (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brooklyn ImmunoTherapeutics reported $0 in long-term debt as of December 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Brooklyn ImmunoTherapeutics, and consider following BTX for alerts when major investors trade the stock.

Brooklyn ImmunoTherapeutics is classified in the Telecommunications sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing BTX with unrelated industries.